LOS ANGELES (Reuters) - Biotechnology giant Amgen Inc (AMGN.O: Quote, Profile, Research) is gearing up for cost cuts as it weathers a siege on its lucrative anemia drug business that accounted for about half of its sales last year.
LOS ANGELES (Reuters) - Biotechnology giant Amgen Inc (AMGN.O: Quote, Profile, Research) is gearing up for cost cuts as it weathers a siege on its lucrative anemia drug business that accounted for about half of its sales last year.
